Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Vodafone Idea shares jump 4%; KM Birla says telco navigated through one of its toughest challenges in history
Vodafone Idea shares climbed after shareholders approved a Rs 4,730 crore investment from the Aditya Birla Group, signalling renewed promoter confidence. With funding support, easing AGR pressure and improved ratings, investor focus now shifts to execution, network expansion and the company’s long-term turnaround prospects.
AB Group reaffirms bet on Voda Idea with ₹4,730 Cr infusion
Vodafone Idea shareholders approved a ₹4,730-crore investment from the Aditya Birla Group via preferential allotment of warrants, increasing AB Group's stake to around 13%. Chairman Kumar Mangalam Birla stated the company's focus now shifts to execution across operations, customer service, and network expansion. This capital infusion will support capital expenditure and loan repayment, reinforcing Vi's financial health.
Market Trading Guide: Akums Drugs among 4 stock recommendations for Thursday
Domestic equities ended lower amid global uncertainty and caution ahead of key US inflation data. Despite market weakness, analysts remain bullish on Akums Drugs and Aditya Birla Sun Life AMC after strong technical breakouts, rising volumes and improving momentum indicators.
Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift
Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.
Grasim announces ₹3,094-cr investment for lyocell capacity expansion in Karnataka plant
The expansion will add 110,000 TPA capacity at Harihar; total cellulosic staple fibre capacity slated to exceed one million tonnes annually by 2030. Grasim Industries, a Aditya Birla Group company, shares closed at ₹3,060.30 on the NSE on June 8, down 0.89%, or ₹27.40.
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row - Mint
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a rowMint
7 most valued firms' mcap eroded ₹1.25 trn last week, RIL took biggest hit
The combined market valuation of seven of the top-10 most-valued firms eroded by Rs 1.25 lakh crore last week, with Reliance Industries taking the biggest hit, in-line with a bearish trend in equities. Last week, the BSE benchmark Sensex declined 532.4 points, or 0.71 per cent, and the NSE Nifty dipped 181.05 points, or 0.76 per cent. "Persistent FII selling remained the key drag on market sentiment despite supportive developments such as cooling crude oil prices and a recovery in the rupee against the US dollar. Concerns regarding the pace of monsoon advancement also weighed on investor confidence," Santosh Meena, Head of Research at Swastika Investmart Ltd, said. From the top-10 pack, Reliance Industries, Bharti Airtel, Tata Consultancy Services (TCS), Bajaj Finance, Larsen & Toubro, Life Insurance Corporation of India (LIC) and Hindustan Unilever faced erosion from their valuation, while HDFC Bank, ICICI Bank, and State Bank of India were the gainers. The market valuation of ...
Stock Market Outlook Next Week, June 8-12: Sensex, Nifty Likely to Remain Weak; Bears Retain Near-Term Control - Goodreturns
Stock Market Outlook Next Week, June 8-12: Sensex, Nifty Likely to Remain Weak; Bears Retain Near-Term ControlGoodreturns
Sai Life, Laurus Labs hit new highs; stocks rally up to 40% in 6 months
Sai's management reiterated long-term guidance of 15-20 per cent revenue CAGR with 28-30 per cent steady state EBITDA margin over the next two to three years.
Small-caps, PSUs and pharma remain Gautam Shah's top market themes for 2026
Gautam Shah, Founder of Goldilocks Global Research, sees the Nifty remaining range-bound between 23,150 and 24,000, while forecasting the small-cap index could rise to 20,000. Shah also believes Indian IT stocks are nearing a bottom and that PSU stocks could deliver 25-30% returns over the next 12-18 months.